Stock SNG SYNAIRGEN PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Synairgen plc

Equities

SNG

GB00B0381Z20

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:20 2024-04-26 am EDT 		5-day change 1st Jan Change
6.49 GBX -1.52% Intraday chart for Synairgen plc -3.85% +8.62%
2023 FTSE 100 Finishes Slightly Lower After Steady Session DJ
2023 Synairgen names Phytome's Joseph Colliver as CFO AN

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Capitalization 1 14.5 6.429 305.9 418.8 27.19 13.07 13.07
Enterprise Value (EV) 1 9.166 3.975 231 385 11.26 13.72 18.57
P/E ratio -3.82 x -1.65 x -16.2 x -8.57 x -1.54 x -1.35 x -
Yield - - - - - 92.4% 108%
Capitalization / Revenue 138 x - - - - - -
EV / Revenue 87.3 x - - - - - -
EV / EBITDA -2.29 x -0.86 x -13.3 x -6.73 x -0.58 x -1.33 x -2.73 x
EV / FCF -2.18 x -1.37 x -9.62 x -9.38 x -0.79 x -1.44 x -3.5 x
FCF Yield -45.9% -73.1% -10.4% -10.7% -127% -69.6% -28.5%
Price to Book 2.09 x 2.85 x 3.59 x 11.3 x - 1.08 x -
Nbr of stocks (in thousands) 109,433 109,433 199,914 201,342 201,375 201,375 201,375
Reference price 2 0.1325 0.0588 1.530 2.080 0.1350 0.0649 0.0649
Announcement Date 2/25/19 5/26/20 5/12/21 5/25/22 4/27/23 - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Net sales 1 0.105 - - - - - -
EBITDA 1 -3.994 -4.61 -17.44 -57.16 -19.28 -10.35 -6.8
EBIT 1 -4.034 -4.706 -17.53 -57.36 -19.38 -10.5 -7
Operating Margin -3,841.9% - - - - - -
Earnings before Tax (EBT) 1 -4.096 -4.793 -17.73 -57.86 -20.09 -11 -
Net income 1 -3.301 -3.885 -13.92 -48.66 -17.64 -9.6 -
Net margin -3,143.81% - - - - - -
EPS 2 -0.0347 -0.0355 -0.0946 -0.2428 -0.0876 -0.0480 -
Free Cash Flow 1 -4.209 -2.906 -24.02 -41.03 -14.29 -9.55 -5.3
FCF margin -4,008.57% - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - 0.0600 0.0700
Announcement Date 2/25/19 5/26/20 5/12/21 5/25/22 4/27/23 - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - 0.65 5.5
Net Cash position 1 5.33 2.45 74.8 33.8 15.9 - -
Leverage (Debt/EBITDA) - - - - - -0.0628 x -0.8088 x
Free Cash Flow 1 -4.21 -2.91 -24 -41 -14.3 -9.55 -5.3
ROE (net income / shareholders' equity) -50.9% -91.7% -31.8% -79% -61.6% -69.4% -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 0.0600 0.0200 0.4300 0.1800 - 0.0600 -
Cash Flow per Share - - - - - - -
Capex 1 - 0.01 0.04 0.02 0.01 - -
Capex / Sales - - - - - - -
Announcement Date 2/25/19 5/26/20 5/12/21 5/25/22 4/27/23 - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0649 GBP
Average target price
0.4 GBP
Spread / Average Target
+516.33%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SYNAIRGEN PLC Stock Synairgen plc
+8.62% 16.28M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SNG Stock
  4. Financials Synairgen plc